About Us

What is Safety Pharmacology?

Safety pharmacology satisfies a key requirement in the process of drug development. Safety pharmacology studies are required to assess the impact of a new chemical entity (NCE) or biotechnology-derived product for human use on vital organ systems before first-in-man drug testing. Safety pharmacology studies are defined as those studies that investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above.

Why a career in Safety Pharmacology?

The field of safety pharmacology has continuously developed since the ratification of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH S7A guidance) in November 2000, as well as the incorporation of the Safety Pharmacology Society in 2001. Since then, demand for safety pharmacologists has only risen. Given the broad scope of safety pharmacology, there will always be opportunity for development and continuous learning will be required to face the challenges of an ever-changing therapeutic landscape, development of new technologies and changing regulatory requirements. For testimonials from individuals working in the pharmaceutical industry and regulatory agencies, please see below.

Although the article linked below applies to the greater field of toxicology, it is very relevant to a discussion of the workforce situation for safety pharmacology. Opportunities Abound in Toxicology, Brian Vastag, United States, June 20, 2008.


The Role of a Safety Pharmacologist in the Pharmaceutical Industry

Safety pharmacology plays a critical role in the pharmaceutical industry, by providing valuable insight into potential adverse effects of drug candidates. These data are used to guide physicians in the safe conduct of clinical trials thru design and execution. A core battery of safety pharmacology tests are required by international regulatory guidelines (ICH S7A/S7B) prior to initiation of the first human dose of an investigational medicine. This core battery of tests includes cardiovascular function, respiratory function (e.g. Plethysmography), and CNS behavior (e.g. Irwin, Functional observational battery). Other supplemental tests may be conducted to assess other organ systems if a need is identified.

Safety pharmacologists may be responsible for planning, conducting, and reporting of in vivo and em>in vitro cardiovascular, respiratory and neurobehavioral assays to evaluate potential unanticipated pharmacodynamic effects of test articles prior to introduction in humans. Additionally, writing detailed scientific reports/manuscripts and preparing documents for regulatory filings both nationally and internationally are frequently required.

Finally, a safety pharmacologist can also perform additional testing aimed at defining the possible mechanisms for unwanted side effects. These types of studies are a stimulating and challenging area of safety pharmacology. Each new drug tested is unique in both mechanistic and therapeutic terms, which means that the safety pharmacologist has an opportunity to develop creative testing strategies. These projects frequently can lead to presentations at internationally renowned meetings and publications in scientific journals.

In terms of day to day work, safety pharmacologists will work with many individuals both within and outside of the company. These individuals include scientific colleagues involved with the daily activities of the core battery of studies. The safety pharmacologist will also collaborate with members from other departments such as toxicology, drug metabolism, basic science and quality assurance in the design and execution of studies both within his organization and at outside contract research organizations. As a study director, the safety pharmacologist will prepare study protocols and write reports on completed studies. In many cases the safety pharmacologist will work within a contract research organization and provide critical expertise for organizations that do not have the specialized in-house capabilities of a safety pharmacologist. The safety pharmacologist will also interact with vendors to troubleshoot technical problems or to discuss new technologies available in the field. As the company expert, he may also be called upon to interact with regulatory agencies to respond to questions as they arise. A safety pharmacologist will have a high impact and dynamic position in any organization whether in a pharmaceutical company or contract research organization.

Pierre Morissette, MSc, PhD
Principal Scientist
Merck & Co., Inc.
Safety and Exploratory Pharmacology

The Role of Safety Pharmacology in a Regulatory Agency (US FDA)

Safety pharmacology studies, which investigate potential undesirable pharmacodynamic effects of a test substance on physiological function in relation to exposure, play an important role in determining whether and how (dose regime, subject selection) a novel test substance can be administered safely to human subjects.

Core studies on key systems (central nervous, respiratory, and cardiovascular systems) constitute an important component of the initial safety evaluation and are reviewed prior to the first administration to human studies. Hazard identification and risk evaluation are key aspects of the evaluation and can be critical in design of clinical trials.

Pharmacologist/toxicologists are tasked with reviewing safety pharmacology studies, and interact with other members of the review team, which include medical officers, clinical pharmacologists, chemists and project managers. Pharmacologists/toxicologists also interact with industry scientists to evaluate specific concerns related to mechanism of action and empirical findings seen in other studies or with similar test substances.

John Koerner, PhD, DSP
Senior Pharmacologist
Division of Cardiovascular and Renal Products Center for Drug Evaluation and Research
US Food and Drug Administration


The Safety Pharmacology Society is a nonprofit organization that promotes knowledge, development, application, and training in safety pharmacology—a distinct scientific discipline that integrates the best practices of pharmacology, physiology and toxicology.


The Society will lead the global safety pharmacology community in the development and safe medical use of biologically active molecular entities.

We will achieve this vision by bridging across disciplines to predict, identify, characterize, monitor, and mitigate potentially undesirable pharmacodynamic activities in nonclinical studies and guiding their translation into clinical trials and beyond, to benefit all patients.

Purpose: Safety pharmacology leaders providing guidance and answers to critical questions that matter to patients, regulators, and scientists.

We move information from data to knowledge to wisdom
Data Knoldege Wisdom graphic


Interactive Strategic Plan  


Strategic Plan

2019—2021 Strategic Goals:

  • Education
  • Partnerships
  • Advancing the Science

Over the next three years, we will focus on delivering the following objectives:

‣ Provide high-quality education opportunities year round
‣ Promote the value of DSP Certification
‣ Promote safety pharmacology expertise as a discipline
‣ Create Value for all members
‣ Expand collaborative opportunities
‣ Expand our global presence
‣ Define Emerging Issues
‣ Use Collective experience to establish and communicate best practices

Strategic Plan and Summary

View the Code of Ethic
View the Constitution & Bylaws
Equality and Diversity Statement

Board of Directors



Brian Roche

Vice President

Todd Wisialowski

Vice President-Elect

Marie-Luce Brodzinski-Rosseels


David John Gallacher


Susan Goody


Annie Delaunois

Past President

Tomas Mow

Board of Directors

Matthew Abernathy, Ray Chui, Tracy Deats, Nicola Fasdelli, Gary Gintant, Kimberly Hoagland, Eric Rossman, Lasse Skibsbye

Executive Director

Krystle Correll


For descriptions and charges for all current SPS Committees, please visit our Committee page.

Please visit SPShare (login required) to view the current Committee Rosters

Our History

Resource Documents
Historical Review: Origins, Practices, and Future of Safety Pharmacology

Past Presidents

  • Tomas Mow
  • Michael Engwall
  • Martin Traebert
  • Will Redfern
  • Michael Pugsley
  • Alfred Botchway
  • Jean-Pierre Valentin
  • Derek J. Leishman
  • Hugo Vargas
  • Mary Jeanne Kallman
  • Kristy Bruse
  • Rick Briscoe
  • Ian MacKenzie
  • Brian Guth
  • R. Dustan Sarazan
  • Lewis B. Kinter
  • Michael R. Gralinski
  • Alan S. Bass
  • Peter K.S. Siegl

Support SPS

With higher levels of sponsorship comes greater attendee exposure. There are five levels of sponsorship available for our Annual Meeting (please reference PDF below)
Download the Safety Pharmacology Society Sponsorship Opportunities

Your personal donation will support SPS strategic initiatives directed toward increasing scientific resources available to those in the field of safety pharmacology, to further our mission, and will support the Society’s needs throughout the year. See more..

Advertising Opportunities

2020 Advertising & Marketing Prospectus

Job Postings

Reach experienced professionals in the safety pharmacology community with 24/7 visibility!

Not just a job listing! By listing your job in the SPS Job Bank & Career Center you can receive a variety of exposure levels for your job:

  • 30-day job posting
  • Email notification to SPS members (~500) featuring new job posting
  • Post to SPS social media accounts (Twitter, Facebook, LinkedIn) featuring new job postings
  • Discounts for Members—contact SPS Headquarters to obtain the discount code
  • Pricing starts at $199!

Submit your job posting Online Now.

Mailing List Rental

Expand Your Reach—An opportunity to market to a targeted, global audience!

Rate: $500 USD per set of mailing labels (SPS membership or SPS Annual Meeting attendees)

Please review our Mailing List Rental Application for additional information.

Vendor Directory

Looking for exposure to potential new customers within the safety pharmacology community? The SPS Vendor Directory is unique because it allows vendors to maximize their marketing dollars by combining online advertising to their target market as well as the opportunity to send out one direct email to SPS Members. Here are a few highlights of the Vendor Directory:

  • The Vendor Directory targets those who are directly connected to the Safety Pharmacology Society as members. Our average member count is 500.
  • You provide the information to ensure the directory is as updated and accurate as possible.
  • Add your logo, business description, services provided, and contact details.
  • Linked directly to your company website.
  • Available online 24/7 and is mobile compatible.
  • Ability to email SPS members directly

Vendor Information Application